Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription.

International journal of immunogenetics - 1 Aug 2014

Darke C, Corbin S A

Abstract excerpt

Hypersensitivity reactions to the drug abacavir are strongly associated with possession of HLA-B*57:01. Hence, patients with HIV/AIDS who may be prescribed abacavir should be tested for this HLA allele and the drug withheld from those that possess B*57:01. The UK National External Quality Assessment Service for Histocompatibility and Immunogenetics has operated a scheme for B*57:01 testing since 2008 which, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Dideoxynucleosides
Share to Drug Hypersensitivity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Histocompatibility Testing

Share to HLA-B Antigens

Share to Quality Control

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 24762294
DOI: 10.1111/iji.12122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription.PMID 24762294Read ↗

External quality assessment of HLA-B*5701 reporting: an international multicentre survey.Semantic proximity Read ↗

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjectsSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy.Semantic proximity Read ↗

The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping MethodsSemantic proximity Read ↗

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.Semantic proximity Read ↗

Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity.Semantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

Novel Sensitive, Specific and Rapid Pharmacogenomic test for the Prediction of Abacavir Hypersensitivity Reaction: HLA-B*57:01 Detection by Real-Time PCRSemantic proximity Read ↗

Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.Semantic proximity Read ↗

Prevalence of HLA-B*57:01 and complete linkage disequilibrium with HCP5 rs2395029: Prevalence and DetectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.